PixarBio Corporation announces that it has terminated its bid for InVivo Therapeutics, due to, as noted in a letter to its shareholders, reasons related to management credibility and competence, corporate governance and IP control.
East Coast-headquartered PixarBio Corporation researches and develops targeted delivery systems for drugs, devices, or biologics to treat pain, epilepsy, Parkinson’s disease, and spinal cord injury, according to a media release from the company.
The aim of InVivo Therapeutics, based in Cambridge, Mass, is to redefine the life of the spinal cord injury patient. Among its latest research is the INSPIRE study of its Neuro-Spinal Scaffold among patients with spinal cord injury.
To read more about the bid termination, visit PixarBio Corporation.
[Source(s): PixarBio Corporation, Business Wire]
